Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 50 21 versus LARIN 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 50 21 versus LARIN 24 FE.
DEMULEN 1/50-21 vs LARIN 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.
None Documented
None Documented
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Ethinyl estradiol: ~13 hours (range 7–20); norethindrone: ~8 hours (range 5–14). Half-life supports once-daily dosing; steady state achieved within 5–7 days.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Ethinyl estradiol: 40% renal, 60% fecal; norethindrone: 40% renal, 60% fecal.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive